emerging microbes & infections

Virology

Pathogens (Basel, Switzerland)

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

[1] Evidence of the Presence of Low Pathogenic Avian Influenza A Viruses in Wild Waterfowl in 2018 in South Africa.

[2] The clinically licensed antifungal drug itraconazole inhibits influenza virus in vitro and in vivo.

[3] Unique synergistic antiviral effects of Shufeng Jiedu Capsule and oseltamivir in influenza A viral-induced acute exacerbation of chronic obstructive pulmonary disease.

[4] affect of early-life oxygen exposure on proper lung development and response to respiratory viral infections

[5] new small-molecule drug design strategies for fighting resistant influenza a

[6] virus shedding in co-infections of low pathogenic avian influenza virus ( h6n2 ) and lentogenic newcastle disease virus (la sota) in numida meleagris

[7] influenza virus segment composition influences viral stability in the environment

[8] immunogenicity and safety of an as03a-adjuvanted h5n1 influenza vaccine in a taiwanese population

[9] initial influenza virus replication can be limited in allergic asthma through rapid induction of type iii interferons in respiratory epithelium

[10] generation of adaptive immune responses following influenza virus challenge is not compromised by pre-treatment with the tlr-2 agonist pam2cys

[11] every breath you take: the impact of environment on resident memory cd8 t cells in the lung

[12] in vitro anti-viral activity of psoraleae semen water extract against influenza a viruses

[13] amino acid substitution k470r in the nucleoprotein increases the virulence of h5n1 influenza a virus in mammals

[14] mucosa-associated lymphoid tissue lymphoma translocation protein 1 positively modulates matrix metalloproteinase-9 production in alveolar macrophages upon toll-like receptor 7 signaling and influenza virus infection

[15] Drug resistance in influenza A virus: the epidemiology and management

[16] Poly-ADP Ribosyl Polymerase 1 (PARP1) Regulates Influenza A Virus Polymerase

[17] Drug resistance in influenza A virus: the epidemiology and management

[18] CD206+ Cell Number Differentiates Influenza A (H1N1)pdm09 from Seasonal Influenza A Virus in Fatal Cases

[19] Full-length human surfactant protein A inhibits influenza A virus infection of A549 lung epithelial cells: A recombinant form containing neck and lectin domains promotes infectivity

[20] p-STAT1 regulates the influenza A virus replication and inflammatory response in vitro and vivo.

[21] Evidence of the Presence of Low Pathogenic Avian Influenza A Viruses in Wild Waterfowl in 2018 in South Africa.

[22] Protection against multiple influenza A virus strains induced by candidate recombinant vaccine based on heterologous M2e peptides linked to flagellin.

[23] Human Heat shock protein 40 (Hsp40/DnaJB1) promotes influenza A virus replication by assisting nuclear import of viral ribonucleoproteins

[24] Sequential Immunizations with heterosubtypic virus-like particles elicit cross protection against divergent influenza A viruses in mice

[25] [The Effects and Mechanisms of Dihydroartemisinin on Influenza A Virus H1N1 Induces TNF-α and IL-6 Expression in Bronchial Epithelial Cells].

[26] (-)-Epigallocatechin-3-gallate induces interferon-λ2 expression to anti-influenza A virus in human bronchial epithelial cells (BEAS-2B) through p38 MAPK signaling pathway.

[27] Obesity Increases the Duration of Influenza A Virus Shedding in Adults

[28] Effect of Clinical and Virological Parameters on the Level of Neutralizing Antibody against Pandemic Influenza A Virus H1N1 2009

[29] immunization of rabbits with synthetic peptides derived from a highly conserved β-sheet epitope region underneath the receptor binding site of influenza a virus

[30] experimental approaches to study genome packaging of influenza a viruses

[31] a case for rimantadine to be marketed in canada for prophylaxis of influenza a virus infection

[32] attenuated recombinant influenza a virus expressing hpv16 e6 and e7 as a novel therapeutic vaccine approach.

[33] correction: attenuated recombinant influenza a virus expressing hpv16 e6 and e7 as a novel therapeutic vaccine approach.

[34] ns segment of a 1918 influenza a virus-descendent enhances replication of h1n1pdm09 and virus-induced cellular immune response in mammalian and avian systems

[35] influenza a virus entry: implications in virulence and future therapeutics

[36] in vitro anti-viral activity of psoraleae semen water extract against influenza a viruses

[37] comparative studies on two tests for detection of avian influenza a virus and newcastle disease virus in co-infected guinea fowl (numida meleagris)

[38] amino acid substitution k470r in the nucleoprotein increases the virulence of h5n1 influenza a virus in mammals

[39] Viral load in patients infected with pandemic H1N1 2009 influenza A virus

[40] Spread of influenza A virus infection in hospitalised patients with cancer

[41] Antiviral agents active against influenza A viruses

[42] Resistant influenza A viruses in children treated with oseltamivir: descriptive study

[43] Common emergence of amantadine- and rimantadine-resistant influenza A viruses in symptomatic immunocompromised adults

[44] Epidemiology of influenza A virus infection in patients with acute or chronic leukemia

[45] Recovery of drug-resistant influenza A virus during therapeutic use of rimantadine